Siegfried to acquire Curia site

Swiss CDMO Siegfried has signed binding agreements with Curia Global for the acquisition of a drug substances site in Grafton, Wisconsin. The deal is expected to close by 1 July, subject to customary closing conditions. No financial details are being disclosed, other than that the acquisition is being financed from existing funds and will not change the company’s outlook for 2024 and mid-term financial targets.

The site employs over 80 and specialises in early-phase development and manufacturing services. Siegfried said that this would strengthen drug substance offer in terms of both capabilities and geographical coverage. It intends to develop the site into a best-in-class hub for early-phase CDMO services, including services for projects with highly potent APIs.

“Siegfried now offers an integrated range of services from early-stage development to commercial production of APIs through to the manufacturing of fully formulated drug products,” commented CFO and acting CEO Reto Suter (pictured). “This transaction will generate attractive opportunities and will further accelerate our growth story.”